Log In
Print this Print this

2661380, AMP-224

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFusion protein that contains the extracellular domain of PD-1 ligand 2 (B7-DC; PDCDILG2) and the Fc-portion of IgG
Molecular Target Programmed cell death 1 ligand 2 (PD-L2) (PDCD1LG2) (B7-DC) ; Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation


GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today